Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
allo-APZ2-CVU for chronic venous leg ulcers
NL-OMON59856Phase 3Active, not recruiting
- Sponsor
- RHEACELL
- Start
- Aug 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in stasis ulcer comparing allo-APZ2-CVU with Placebo (2 arms). Primary endpoints: Complete wound closure at Week 18 persisting for at least two weeks and Adverse events. Started Aug 2025; status: active, not recruiting.
02
Drugs
EBESANAR
03
Conditions
stasis ulcer
Beyond the preview
Go deeper on NL-OMON59856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59856.